Straumann Holding AG stock (CH0012280076): Steady growth in dental implant market

Straumann Holding AG maintains its position as a key player in the dental technology sector, focusing on implants, orthodontics, and digital dentistry solutions. The company reported steady performance in its core markets, with shares trading at around 122.50 CHF on the SIX Swiss Exchange as of May 8, 2026, according to SIX Group as of 05/08/2026.

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

Straumann Holding AG: core business model

Straumann Holding AG develops, manufactures, and distributes dental implants, restorative products, orthodontics, and digital solutions worldwide. The company emphasizes premium biomaterials and digital workflows to support dental professionals. Its Straumann® Dental Implant System remains a cornerstone, used in over 100 countries, according to the company investor page as of 05/2026.

Business operations span three main segments: Implant Solutions, Orthodontics, and Digital. Implant Solutions generates the majority of revenue through titanium-zirconium implants and regenerative materials. Orthodontics includes clear aligner systems like ClearCorrect, competing in the growing aesthetic dentistry space.

Main revenue and product drivers for Straumann Holding AG

Premium implants and tissue regeneration products drive over 60% of revenue, with strong demand in North America and China. For full-year 2025 (published February 2026), the company posted net sales of CHF 2.4 billion, up 8% at constant exchange rates, per Straumann IR report 02/27/2026. Digital dentistry tools, including intraoral scanners, contribute growing high-margin sales.

Geographic expansion bolsters growth, with Asia-Pacific now over 30% of sales. Acquisitions like Anthogyr have enhanced the portfolio in value segments, supporting penetration in emerging markets.

Industry trends and competitive position

The global dental implant market is projected to reach $8 billion by 2028, driven by aging populations and aesthetic procedures, according to Statista as of 03/2026. Straumann competes with Nobel Biocare (Danaher) and Dentsply Sirona, holding a leading share in premium segments through innovation and R&D investment exceeding 10% of sales.

Straumann's focus on digital integration positions it well against disruptors like Align Technology in orthodontics. US investors note its Nasdaq-listed peers and exposure to American dental chains.

Why Straumann Holding AG matters for US investors

Straumann derives about 20% of revenue from North America, benefiting from US demand for cosmetic dentistry. Listed on SIX, shares are accessible via US brokers, offering diversification into medtech with Swiss stability. Its products support major US practices, linking to domestic healthcare spending trends.

Conclusion

Straumann Holding AG demonstrates resilience in the dental sector through premium products and geographic diversification. With solid 2025 results and digital expansion, it remains relevant for medtech exposure. Investors track upcoming Q1 2026 earnings for growth confirmation amid currency and competitive pressures.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.